表紙
市場調査レポート

3Dバイオプリンティング市場

3D Bioprinting Market, 2014 - 2030

発行 ROOTS ANALYSIS 商品コード 297236
出版日 ページ情報 英文 140 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
3Dバイオプリンティング市場 3D Bioprinting Market, 2014 - 2030
出版日: 2014年03月05日 ページ情報: 英文 140 Pages
概要

当レポートでは、新興する3Dバイオプリンティング市場について、特に業務用バイオプリンターと開発中の製品、アプリケーションおよび将来の進化に注目して調査しており、技術進歩、製品パイプライン、産学研究プログラムおよび規制上の懸念事項などについて分析し、概略下記の構成で取り上げております。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場概要

  • 本章の概要
  • 市場におけるわずかな専門(プロ向け)バイオプリンター
  • 価格は非常に高額
  • 米国がリード:発展途上諸国が貢献を始める
  • 新興企業がキープレイヤーとして登場
  • バイオプリンティング:大学研究におけるルーツの発見
  • マルチアームバイオプリンターの開発:次世代のバイオプリンター

第5章 プロファイル:業務用バイオプリンター・製品

  • 本章の概要
  • Novogen MMX - Organovo
  • 3D-Bioplotter - EnvisionTEC
  • BioFactory - regenHU
  • BioAssembly Tool - Sciperio / nScrypt
  • マイクロ流体ベースのバイオプリンティングプラットフォーム:Aspect Biosystems
  • モディファイドインクジェット式バイオプリンター:TeVido BioDevices
  • その他のイニシアチブ

第6章 製品プロファイル:学問機関

  • 本章の概要
  • BioPen:University of Wollongong / St. Vincent Hospital
  • 皮膚細胞向けモディファイドインクジェット式バイオプリンター:Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
  • 組織・臓器向けモディファイドインクジェット式バイオプリンター:Wake Forest Institute for Regenerative Medicine
  • Regenovo:Hangzhou Dianzi University、中国
  • バルブ型技術:Heriot-Watt University / Roslin Cellab

第7章 市場予測

  • 本章の概要
  • 予測手法
  • 3Dバイオプリンティング市場

第8章 SWOT分析

  • 本章の概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第9章 ケーススタディ

  • Organovo Holdings, Inc.
  • regenHU

第10章 インタビュー記録

  • インタビュー 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
  • インタビュー 2: regenHU (Marc Thurner, CEO)
  • インタビュー 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
  • インタビュー 4: MicroFab Technologies (Anonymous)
  • インタビュー 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
  • インタビュー 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)

第11章 結論

  • 3Dバイオプリンティングは開始以来うまく出現
  • 業務用バイオプリンターはわずか:調査ラボおよび大学研究からのスピンアウトが進歩を続ける
  • 臓器の需給格差:主な成長の促進因子
  • 2030年までに全体で数十億ドル規模の機会
  • バイオプリンティングが主流になる前に存在する問題

第12章 付録1:企業・組織のリスト

第13章 付録?:図表

図表リスト

目次
Product Code: RA10011

The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. This report suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.

Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man's skull.

Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.

Synopsis:

The ‘3D Bioprinting, 2014 - 2030’ report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities.

One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following:

  • Commercial 3D Bioprinters currently available in the market
  • Innovations of academic groups across various research institutes across the globe
  • Competing technologies with similar applications in the healthcare industry
  • Size of target consumer segments
  • The widening supply-demand gap, specifically for organ transplants.

The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.
  • 2. A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).
  • 3. The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.
  • 4. As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.
  • 5. We believe that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.
  • 6. By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • 1. Annual reports
  • 2. Investor presentations
  • 3. SEC filings
  • 4. Industry databases
  • 5. News releases from company websites
  • 6. Government policy documents
  • 7. Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D bioprinting market is headed in the mid-long term.

Chapter 3 provides a general introduction to 3D bioprinting. We have discussed, in detail, the origins of 3D printing and recent developments which have shaped the industry so far. The chapter also elaborates on the ‘bioprinting' process, current and future applications, and the challenges which have to be overcome before wider adoption of the technology.

Chapter 4 provides an overview of the 3D bioprinting market with respect to the available bioprinting technologies and companies active in the field. The analysis also extends to regional evolution and the key drivers which will determine the future growth.

Chapter 5 offers a comprehensive review of the major bioprinters which have been made available by leading companies in the market. We present profiles of eight technologies with information about their origin, printing process, applications, principal features, current status and expected future evolution.

Chapter 6 reviews, in detail, the major bioprinters offered by academic institutions dominant in the field. We present profiles of five leading technologies with information about their origin, printing process, applications, principal features, current status and likely future evolution.

Chapter 7 analyses the current and future state of the worldwide market of 3D bioprinting. The chapter includes our estimates of the value of the market for end-user applications till 2030. Given the current niche nature of the technology, we have done a multi-variate sensitivity analysis to present three different tracks of industry's evolution.

Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the 3D bioprinting market, capturing the key elements likely to influence future growth.

Chapter 9 provides case studies on Organovo and regenHU, two companies active in the 3D bioprinting arena. The case studies include detailed analysis of financial performance (where available), marketed / pipeline bioprinting products, recent developments, and future focus areas.

Chapter 10 is a collection of six transcripts based on our discussion with some of the leading players in the industry. The companies / academic institutes interviewed include n3D Biosciences, regenHU, Sciperio / nScrypt, MicroFab Technologies, Digilab and TeVido BioDevices.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

SAMPLES

Figure 4.3:
University Sponsored Bioprinters: Regional Distribution

Source: Roots Analysis

Figure 7.1:
Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)

Source: Roots Analysis

Table of Contents

1. PRELUDE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. 3D Printing Technology
    • 3.2.1. What is 3D Printing?
    • 3.2.2. Historical Evolution
  • 3.3. 3D Bioprinting Process And Components
  • 3.4. Entry of 3D Printing into Medical Arena
    • 3.4.1. Key Players
    • 3.4.2. 3D Bioprinting Applications
      • 3.4.2.1. Toxicity Screening / Drug Testing
      • 3.4.2.2. Tissue Engineering
      • 3.4.2.3. Organ Replacement via Organ Printing
    • 3.4.3. Challenges
      • 3.4.3.1. High Initial Cost
      • 3.4.3.2. Regulatory Issues
      • 3.4.3.3. Functional Aspects Not Yet Fully Tested
      • 3.4.3.4. Limited Capability for Complicated Tissues and Organs
      • 3.4.3.5. Hurts Moral and Religious Beliefs

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Limited Professional Bioprinters in Market
  • 4.3. Prices are Largely Prohibitive
  • 4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
  • 4.5. Start-ups Emerging as Key Players
  • 4.6. Bioprinting: Finding its Root in University Research
  • 4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters

5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS

  • 5.1. Chapter Overview
  • 5.2. Novogen MMX - Organovo
    • 5.2.1. Overview and Origin
    • 5.2.2. Development of NovoGen MMX
    • 5.2.3. Patents
    • 5.2.4. Awards and Accomplishments
    • 5.2.5. The Bioprinting Process
    • 5.2.6. Bio-ink
    • 5.2.7. Key Features
    • 5.2.8. Applications
      • 5.2.8.1. Microtissues for Drug Discovery and Research
      • 5.2.8.2. Longer Term, Organ Printing for Transplantation
      • 5.2.8.3. Regenerative Medicine
    • 5.2.9. Partnerships and Agreements
      • 5.2.9.1. Pfizer
      • 5.2.9.2. United Therapeutics
      • 5.2.9.3. Autodesk
      • 5.2.9.4. ZenBio
      • 5.2.9.5. OHSU
      • 5.2.9.6. Roche
      • 5.2.9.7. Methuselah Foundation
      • 5.2.9.8. NIH
  • 5.3. 3D-Bioplotter - EnvisionTEC
    • 5.3.1. Overview and Origin
    • 5.3.2. The Bioprinting Process
    • 5.3.3. Applications
      • 5.3.3.1. Provides ‘smart' scaffolds for tissue engineering
      • 5.3.3.2. Cell and Tissue Printing
      • 5.3.3.3. 3D-Anatomical Models for Study
    • 5.3.4. Key Features
    • 5.3.5. Academic Institutions using 3D Bioplotter
  • 5.4. BioFactory - regenHU
    • 5.4.1. Overview and Origin
    • 5.4.2. Features
    • 5.4.3. Research Collaborations
      • 5.4.3.1. ETH, Zurich
      • 5.4.3.2. ZHAW
    • 5.4.4. Applications
  • 5.5. BioAssembly Tool - Sciperio / nScrypt
    • 5.5.1. Overview and Origin
    • 5.5.2. The Bioprinting Process
    • 5.5.3. Key Features
      • 5.5.3.1. SmartPump
    • 5.5.4. Collaborations
      • 5.5.4.1. Cardiovascular Innovation Institute
    • 5.5.5. Awards / Accomplishments
    • 5.5.6. Applications
      • 5.5.6.1. Bioficial Heart
      • 5.5.6.2. Other Tissues
  • 5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
    • 5.6.1. Overview and Origin
    • 5.6.2. The Bioprinting Process
    • 5.6.3. Key Features
    • 5.6.4. Building Tissue Constructs For Drug Discovery
    • 5.6.5. Awards
      • 5.6.5.1. MEMSCAP Design Award 2013
      • 5.6.5.2. Federal Support Through IRAP
  • 5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
    • 5.7.1. Overview and Origin
    • 5.7.2. Awards/Accomplishments
    • 5.7.3. The Bioprinting Process
    • 5.7.4. Key Features
    • 5.7.5. Applications
      • 5.7.5.1. Breast Reconstruction
      • 5.7.5.2. Drug Testing
      • 5.7.5.3. Other Reconstructive Tissue Products
      • 5.7.5.4. Treatment for Chronic Wounds
      • 5.7.5.5. Breast Augmentation
  • 5.8. Other Initiatives
    • 5.8.1. SkinPrint
    • 5.8.2. 3DDiscovery - regenHU
      • 5.8.2.1. Key Features
      • 5.8.2.2. Research Collaborations

6. PRODUCT PROFILES: ACADEMIC INSTITUTES

  • 6.1. Chapter Overview
  • 6.2. BioPen - University of Wollongong / St. Vincent Hospital
    • 6.2.1. Overview and Origin
    • 6.2.2. The Bioprinting Process
    • 6.2.3. Advantages of BioPen
    • 6.2.4. Applications
  • 6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
    • 6.3.1. Overview
    • 6.3.2. The Bioprinting Process
    • 6.3.3. Key Features
    • 6.3.4. Bioprinting Human Skin
    • 6.3.5. Awards / Accomplishments
  • 6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
    • 6.4.1. Overview
    • 6.4.2. The Bioprinting Process
    • 6.4.3. Applications
      • 6.4.3.1. Tissue Patches
      • 6.4.3.2. Potential to Print Organs
      • 6.4.3.3. Organs on a Chip
    • 6.4.4. Awards/Accomplishments
  • 6.5. Regenovo - Hangzhou Dianzi University, China
    • 6.5.1. Overview
    • 6.5.2. The Bioprinting Process
    • 6.5.3. Key Features
    • 6.5.4. Limitations
    • 6.5.5. Applications
  • 6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
    • 6.6.1. Overview and Origin
    • 6.6.2. The Bioprinting Process
    • 6.6.3. Key Features
    • 6.6.4. Applications
      • 6.6.4.1. Drug Testing for Pharmaceutical Research
      • 6.6.4.2. Tissue Regeneration
      • 6.6.4.3. Custom-built Replacement Organs
    • 6.6.5. Awards / Accomplishments
    • 6.6.6. Collaborations
      • 6.6.6.1. Reinnervate Ltd.

7. MARKET FORECAST

  • 7.1. Chapter Overview
  • 7.2. Forecast Methodology
  • 7.3. The 3D Bioprinting Market, 2014 - 2030
    • 7.3.1. Background
    • 7.3.2. Market Forecast: Drug Testing (Base Scenario)
    • 7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
    • 7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
    • 7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
    • 7.3.6. Overall Market Forecast (Base Scenario)

8. SWOT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Strengths
    • 8.2.1. Faster Drug Discovery
    • 8.2.2. A Quality Alternative to Animal Testing
  • 8.3. Weaknesses
    • 8.3.1. High Initial Investment
    • 8.3.2. Integration of Vascular Network
  • 8.4. Opportunities
    • 8.4.1. Low Entry Barriers
    • 8.4.2. Growing Wait List for Organ Transplants - A Huge Unmet Need
  • 8.5. Threats
    • 8.5.1. Regulatory Barrier
    • 8.5.2. Commercial 3D Cell Culture Systems

9. CASE STUDIES

  • 9.1. Organovo Holdings, Inc.
  • 9.2. regenHU

10. INTERVIEW TRANSCRIPTS

  • 10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
  • 10.2. Interview 2: regenHU (Marc Thurner, CEO)
  • 10.3. Interview 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
  • 10.4. Interview 4: MicroFab Technologies (Anonymous)
  • 10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
  • 10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)

11. CONCLUSION

  • 11.1. 3D Bioprinting has Emerged Well Since Inception
  • 11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
  • 11.3. Organ Supply - Demand Gap: A Major Growth Driver
  • 11.4. Overall a Multi-billion Dollar Opportunity by 2030
  • 11.5. Challenges Exist Before Bioprinting Becomes Mainstream

12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS

13. APPENDIX 2: TABLES

List of Figures:

  • Figure 3.1: The ‘Bioprinting' Process
  • Figure 4.1: Industry Sponsored Bioprinters: Regional Distribution
  • Figure 4.2: Industry Sponsored Bioprinters: Distribution by Status
  • Figure 4.3: University Sponsored Bioprinters: Regional Distribution
  • Figure 5.1: Bioplotter: Printing Process
  • Figure 7.1: Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
  • Figure 7.2: Drug Testing Market, Long Term, Base Scenario (USD MM)
  • Figure 7.3: 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
  • Figure 7.4: 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
  • Figure 7.5: 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
  • Figure 7.6: 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
  • Figure 7.7: 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
  • Figure 7.8: Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
  • Figure 7.9: Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
  • Figure 10.1: Process of Magnetic Bioprinting
  • Figure 10.2: 3D Cell Bioprinting: Magnetically Beyond Rings and Dots
  • Figure 10.3: n3D vs. Organovo 3D Bioprinting
  • Figure 11.1: 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)
  • Figure 11.2: 3D Bioprinting: The Driving Forces

List of Tables:

  • Table 3.1: RepRap Project: 3D Printing Machines
  • Table 3.2: Inputs for 3D Bioprinting
  • Table 4.1: List of Bioprinters: Industry Sponsored
  • Table 4.2: Companies Developing Bioprinted Products for Commercial Purposes
  • Table 4.3: Universities Working in the Area of Bioprinting
  • Table 5.1: NovoGen MMX: Patent Portfolio
  • Table 5.2: Materials Used for Scaffolds
  • Table 5.3: SmartPump - Models and Features
  • Table 7.1: 3D Bioprinted Applications: Launch Timeline
  • Table 7.2: 3D Bioprinted Skin: Competitive Landscape
  • Table 8.1: SWOT Analysis
  • Table 8.2: 3D Cell Culture Systems
  • Table 9.1: 3D Liver Assays - Launch Timeline
  • Table 9.2: Organovo's Plans for Revenue Generation from 3D Bioprinted Liver
  • Table 9.3: Organovo Revenues - 2011, 2012, and Q1 2013
  • Table 9.4: regenHU: 3D Bioprinting Product Portfolio
  • Table 13.1: Industry Sponsored Bioprinters: Regional Distribution
  • Table 13.2: Industry Sponsored Bioprinters: Distribution by Status
  • Table 13.3: University Sponsored Bioprinters: Regional Distribution
  • Table 13.4: Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
  • Table 13.5: Drug Testing Market, Long Term, Base Scenario (USD MM)
  • Table 13.6: Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)
  • Table 13.7: Drug Testing Market, Long Term, Conservative Scenario (USD MM)
  • Table 13.8: Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)
  • Table 13.9: Drug Testing Market, Long Term, Optimistic Scenario (USD MM)
  • Table 13.10: 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
  • Table 13.11: 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
  • Table 13.12: 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)
  • Table 13.13: 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)
  • Table 13.14: 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)
  • Table 13.15: 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)
  • Table 13.16: 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
  • Table 13.17: 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
  • Table 13.18: 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)
  • Table 13.19: 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)
  • Table 13.20: 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)
  • Table 13.21: 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)
  • Table 13.22: 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
  • Table 13.23: 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)
  • Table 13.24: 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)
  • Table 13.25: 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
  • Table 13.26: 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
  • Table 13.27: 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)
  • Table 13.28: 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)
  • Table 13.29: 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)
  • Table 13.30: 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)

The following companies have been mentioned in the report.

  • 1. 3D Biotek
  • 2. 3D Systems
  • 3. Advanced Biomatrix
  • 4. Amgen
  • 5. Aspect Biosystems
  • 6. Asyril
  • 7. Autodesk
  • 8. Avita Medical
  • 9. BD Biosciences
  • 10. Bespoke Innovations
  • 11. Bio3D Technologies
  • 12. CellASIC
  • 13. CMC Microsystems
  • 14. Cornell
  • 15. CP Automation
  • 16. Cuspis LLC
  • 17. Cyfuse Biomedical
  • 18. Cyprotex
  • 19. Digilab
  • 20. DTM
  • 21. EnvisionTEC
  • 22. GlycosanBiosystems
  • 23. Hangzhou Dianzi University, China
  • 24. Helisys Inc.
  • 25. Heriot-Watt University
  • 26. i.materialise
  • 27. ImmunoGen
  • 28. InSphero AG
  • 29. Invetech
  • 30. Invetechon
  • 31. Invitrogen
  • 32. Kor Ecologic
  • 33. Layerwise
  • 34. MakerBot Industries
  • 35. Mayoclinic
  • 36. Methuselah Foundation
  • 37. MicroFab Technologies
  • 38. Modern Meadows
  • 39. n3D Biosciences
  • 40. Nano3D Biosciences
  • 41. National Institute of Health
  • 42. Neatco
  • 43. NovoGen
  • 44. Objective 3D
  • 45. Objet Geometries Ltd
  • 46. Organovo Holdings, Inc.
  • 47. Oregon Health & Science University
  • 48. Oxford Performance Materials
  • 49. Pfizer
  • 50. QGel
  • 51. Rainbow Biosciences
  • 52. regenHU
  • 53. Reinnervate
  • 54. Roche
  • 55. Roland DG Corporation
  • 56. Roslin Cellab
  • 57. Sanofi
  • 58. Sciperio / nScrypt
  • 59. Scivax
  • 60. Seattle Genetics
  • 61. SkinPrint
  • 62. Solidscape
  • 63. Stratasys
  • 64. Tengion
  • 65. TeVido BioDevices
  • 66. The Technology Partnership
  • 67. Unique Technology
  • 68. United Therapeutics
  • 69. Vidi
  • 70. Vivos Dental
  • 71. Wake Forest Institute for Regenerative Medicine
  • 72. Widex
  • 73. Xilloc
  • 74. Xillocto
  • 75. Z Corporation
  • 76. ZenBio
  • 77. Zurich University of Applied Sciences
  • 78. Zyoxel
Back to Top